Literature DB >> 22816789

Molecular characterization of central neurocytomas: potential markers for tumor typing and progression.

Alexandre Vasiljevic1, Jacques Champier, Dominique Figarella-Branger, Anne Wierinckx, Anne Jouvet, Michelle Fèvre-Montange.   

Abstract

Central neurocytomas (CNs) are rare intraventricular tumors presenting a favorable prognosis after surgery. Their transcriptomic profile is poorly characterized. We performed a microarray transcriptomic study to search for molecular markers that might improve diagnostic accuracy. Microarray analysis was performed on five CNs (3 primary and 2 recurrent CNs) using CodeLink human whole genome bioarrays, and the gene expression in CNs was compared with that in four pineal parenchymal tumors, consisting of two pineocytomas (PCs) and two pineoblastomas (PBs), other periventricular tumors which may present neuronal differentiation. We identified genes that were highly expressed in CNs compared to normal brain and might be candidates for the molecular typing of CNs. Several genes are part of the Wnt/β-catenin and sonic hedgehog signaling pathways or mainly linked to calcium function or maintenance of neural progenitors. Moreover, several genes are overexpressed in both CNs and PCs and/or PBs such as INSM1 and NEUROD4, involved in neural or neuroendocrine differentiation. The overexpression of eight candidate genes in CNs (CHRDL2, IGF2, KiSS-1, CAL2, NTS, NHLH1, RGS16 and SCGN) was confirmed by real-time RT-PCR. Of the genes overexpressed in the recurrent CNs compared to the primary CNs, AQP5, KiSS-1, FZD7, AURKB, UBE2C and PTTG1 are genes which may be involved in tumor progression. Our study shows the potential involvement of various genes in the pathogenesis of CNs. These genes could be potential candidate markers for improving the characterization of CNs and some could be involved in CN tumorigenesis.
© 2012 Japanese Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22816789     DOI: 10.1111/j.1440-1789.2012.01338.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  9 in total

1.  Deep Sc-RNA sequencing decoding the molecular dynamic architecture of the human retina.

Authors:  Lulin Huang; Runze Li; Lin Ye; Shanshan Zhang; Huaping Tian; Mingyan Du; Chao Qu; Shujin Li; Jie Li; Mu Yang; Biao Wu; Ran Chen; Guo Huang; Ling Zhong; Hongjie Yang; Man Yu; Yi Shi; Changguan Wang; Houbin Zhang; Wei Chen; Zhenglin Yang
Journal:  Sci China Life Sci       Date:  2022-09-15       Impact factor: 10.372

2.  Atypical central neurocytoma with novel EWSR1-ATF1 fusion and MUTYH mutation detected by next-generation sequencing.

Authors:  Yasmin Aghajan; Denise M Malicki; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2019-01-14

3.  UBE2S is associated with malignant characteristics of breast cancer cells.

Authors:  Akter Khondker Ayesha; Toshinori Hyodo; Eri Asano; Naoki Sato; Mohammed A Mansour; Satoko Ito; Michinari Hamaguchi; Takeshi Senga
Journal:  Tumour Biol       Date:  2015-08-06

4.  Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.

Authors:  Melissa Schmidt; Andreas Mock; Christine Jungk; Felix Sahm; Anna Theresa Ull; Rolf Warta; Katrin Lamszus; Konstantinos Gousias; Ralf Ketter; Saskia Roesch; Carmen Rapp; Sebastian Schefzyk; Steffi Urbschat; Bernd Lahrmann; Almuth F Kessler; Mario Löhr; Christian Senft; Niels Grabe; David Reuss; Philipp Beckhove; Manfred Westphal; Andreas von Deimling; Andreas Unterberg; Matthias Simon; Christel Herold-Mende
Journal:  Oncotarget       Date:  2016-03-22

5.  UBE2C induces EMT through Wnt/β‑catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A.

Authors:  Rui Wang; Yue Song; Xi Liu; Qixue Wang; Yunfei Wang; Liwei Li; Chunsheng Kang; Qingyu Zhang
Journal:  Int J Oncol       Date:  2017-02-17       Impact factor: 5.650

Review 6.  The role of chemotherapy in the treatment of central neurocytoma.

Authors:  Margaret O Johnson; John P Kirkpatrick; Mallika P Patel; Annick Desjardins; Dina M Randazzo; Henry S Friedman; David M Ashley; Katherine B Peters
Journal:  CNS Oncol       Date:  2019-11-05

7.  Comprehensive Pan-Cancer Analysis of the Prognostic and Immunological Roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis.

Authors:  Xiulin Jiang; Yixiao Yuan; Lin Tang; Juan Wang; Qianqian Liu; Xiaolan Zou; Lincan Duan
Journal:  Front Cell Dev Biol       Date:  2021-11-10

8.  High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.

Authors:  Zhihua Shen; Xiaofan Jiang; Chao Zeng; Shaojiang Zheng; Botao Luo; Yumei Zeng; Ranran Ding; Hanguo Jiang; Qiyi He; Junli Guo; Wei Jie
Journal:  BMC Cancer       Date:  2013-04-15       Impact factor: 4.430

9.  Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494.

Authors:  Yifeng Bai; Yanqin Sun; Juan Peng; Hongzhan Liao; Hongyi Gao; Ying Guo; Linlang Guo
Journal:  Oncotarget       Date:  2014-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.